Merck is pricing the new drug at $14,000 per vial. The annual cost for most patients eligible for the drug will be approximately $240,000.
The FDA has approved sotatercept, a new treatment for pulmonary arterial hypertension.
Merck is selling the drug under the brand name Winrevair.
Merck is pricing the drug at $14,000 per vial, before any rebates or discounts.
Merck says that approximately two-thirds of patients will need to be treated with a vial every three weeks. At that frequency, the annual cost would add to up approximately $240,000.
Pulmonary arterial hypertension (PAH) is a characterized by high blood pressure in the arteries of the lungs. PAH usually affects women between the ages of 30 and 60, according to the National Organization of Rare Disorders.
Today’s approval came just a day after the FDA approved Opsynvi for PAH. A Johnson & Johnson product, Opsynvi combines macitanten and tadalafil, which are commonly prescribed to treat PAH. Tadalafil is also an erectile dysfunction drug that is sold under the brand name Cialis.
Merck said in a press release today that Winrevair would be available from select specialty pharmacies by the end of next month,
The drug is administered by subcutaneous (under the skin) injection.The Merck press release says it can be administered by patients or caregivers with guidance, training and follow-up from a healthcare provider.
This is a developing story.
Medicaid Unwinding Linked to Prescription Loss in Children and Young Adults, Study Shows
May 2nd 2025Children and young adults living in states with the biggest drops in Medicaid coverage experienced more prescription disruptions for their chronic conditions than those living in states with smaller drops, according to a new study by researchers at the University of Michigan.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen